Recurrence of childhood ear and throat infections such as
glue ear and tonsilitis could be reduced by about 40% and 90%
respectively through using the Blis K12 probiotic, an
independent research study has shown.
The findings of a study by an Italian research team were
published this month in the International Journal of
The study, conducted over three years, involved 82 children
aged between 4 and 5 years, with a history of recurrent ear
and throat infection, who were recruited to determine the
effect of 90 days of treatment with either the Blis K12
probiotic or a placebo. Barry Richardson, chief executive of
the Dunedin-based biotechnology company, said the company
knew that K12, when taken on a daily basis, was very
effective at establishing itself inside the mouth and throat.
The success of the product was also getting through to
mainstream New Zealand consumers. Market research data showed
while the cough and cold market contracted by 1% for the 12
months to September, the Blis Throat Guard range of Blis K12
probiotic lozenges grew 11.6% in unit sales over the past
year, Dr Richardson said. In October, Blis Technologies
announced it had teamed up with the Salvation Army to help
fight the battle against tonsilitis and rheumatic fever.
It has been providing some children and their families in
Otago and Southland with free probiotic lozenges. The
families were identified by the Salvation Army as being in
need of additional welfare and were likely to be at higher
risk from tonsilitis.